Researchers are exploring the potential of proteolysis-targeting chimeras, or PROTACs, in the treatment of leukemia. Studies are investigating the use of PROTACs to target and degrade specific proteins involved in the disease, with some focusing on their activity in acute myeloid leukemia and others on their potential to suppress oncogenic gene expression. The role of PROTACs in hematologic malignancies is an emerging area of research, with various studies and clinical trials underway to evaluate their effectiveness.